Annual Report

Overview

The report describes a challenging 2014, with consolidated net sales falling to CHF 315.3 million while the EBITDA margin increased to 18.6%. It highlights the end-November acquisition of Hameln Pharma and continued investment in Nantong and Zofingen to expand the sterile-filling and active-pharmaceutical-ingredient network. The Sustainability Report covers safety, environmental protection, and employees, with environmental figures reported for four production sites.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2014
Period: Ends 31 December 2014
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services